You are here


Generic drug group AAM chooses Dan Leonard as its next CEO

Leonard has been CEO of National Pharmaceutical Council since 2008.


Aug. 25, 2020
By Lori Sharn

The trade group for the generic and biosimilar drug industry announced that Dan Leonard will become CEO of the Association for Accessible Medicines in September.

Leonard has been CEO of the National Pharmaceutical Council for more than 12 years. He succeeds Chip Davis, who left AAM in February to become CEO of the Healthcare Distribution Alliance. AAM reported revenue of $27 million in 2018.

“During our search for a CEO, AAM has been ably led by its Senior Vice President and General Counsel, Jeff Francer, and we thank him for taking on the additional responsibilities,” Carol Lynch, vice chair of the AAM board, said in the Aug. 25 announcement. “We are confident that Dan will lead the association’s talented team to support our work with the Administration and Congress to further secure the pharmaceutical supply chain and create market conditions that will ensure the long-term viability of the generic and biosimilars industry.”

The National Pharmaceutical Council is a health policy research organization supported by major biopharmaceutical companies. Before joining NPC in 2008, Leonard was executive vice president of advocacy and professional services at America’s Health Insurance Plans.

His background includes time at communications firm Edelman, being chief of staff for former Rep. Susan Molinari (R-NY) and a television reporter in New Hampshire. Leonard has a master’s degree in government from Johns Hopkins University.

Korn Ferry assisted in the search.